NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE American · Biotechnology · USD

Protalix BioTherapeutics, Inc. (PLX) Stock Analysis

Protalix BioTherapeutics, Inc. (PLX) is a Biotechnology stock listed on NYSE American and quoted in US Dollar.

PLX

$2.67

+$0.05 (+1.91%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PLX with… →

PLX Key Statistics

As of Sep 4, 2026
Trading
Open
$2.62
Previous Close
$2.62
Day's Range
2.62–2.68
52-Week Range
1.53–3.19
Volume
863.20K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.02
Valuation
Market Cap
$215.13M
P/E Ratio
11.61
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
4.31
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.67
EPS (ttm)Profit attributable to each share over the last twelve months.
0.23
Financials (FY)
Revenue (FY)
$52.74M−1.23%
Net Income (FY)
−$6.60M−325.24%
Profit marginThe share of revenue left as profit after all costs and taxes.
23.50%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
80.57M
1-Year Return
+67.92%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
678.78K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

PLX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+48.33%
2025−4.26%
2024+5.62%
2023+29.93%
2022+65.06%
2021−77.13%
2020+10.67%
2019+5.81%
2018−53.03%
2017+46.67%
2016 (partial year)−29.69%

As of September 4, 2026.

PLX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$52.74M−$6.60M−12.5%
2024$53.40M$2.93M5.5%
2023$65.49M$8.31M12.7%
2022$47.64M−$14.93M−31.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$52.74M$25.75M−$5.50M−$6.60M−12.5%
2024$53.40M$29.08M$3.92M$2.93M5.5%
2023$65.49M$42.51M$10.46M$8.31M12.7%
2022$47.64M$28.05M−$13.01M−$14.93M−31.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

PLX Valuation vs Biotechnology Median

Median of 656 stocks
MetricPLXBiotechnology medianvs median
P/E11.6112.578% below
P/S ratio2.6715.260.2x the median
Profit margin23.50%0.00%23.5 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Protalix BioTherapeutics, Inc. (PLX) carries a market capitalisation of $215.13M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 226 employees.

The 52-week range on file runs from $1.53 to $3.19. PLX last closed at $2.67 on September 4, 2026. That is +$0.05 (+1.91%) against the previous close. The latest close sits 74.51% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $52.74M. That is −1.23% against the prior fiscal year, when revenue was $53.40M. The same year closed with a net loss of $6.60M. The reported profit margin is 23.5%. That is 23.5 percentage points above the Biotechnology median of 0%. Earnings per share on a trailing basis come to 0.23.

Across the 4 fiscal years on file, revenue moves from $47.64M in 2022 to $52.74M in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 11.61 times earnings. That is 7.64% below the Biotechnology median of 12.57. On forward earnings the ratio is 4.31. Measured against sales, the shares trade at 2.67 times revenue. On price-to-sales that is 0.2 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is +67.92%. Measured over 10 years, that is −7.78% a year compounded. The reported beta is 0.02. Daily returns over the trailing 10 years annualize to a volatility of 80.05%.

Growth & Income

No dividend is on file for PLX.

The strongest complete calendar year on file is 2022 at +65.06%; the weakest is 2021 at −77.13%. Of the 9 complete calendar years on file, 6 finished higher. 2026 is still running; the price is +48.33% year to date.

Peer Comparison

Protalix BioTherapeutics, Inc. (PLX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Protalix BioTherapeutics, Inc. PLX $215.13M 11.6
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Protalix BioTherapeutics, Inc. trades at a P/E of 11.6.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.

Visit website →